Skip to main content
Top
Published in: Annals of Hematology 6/2004

01-06-2004 | Original Article

Evidence for a metabolic shift of arginine metabolism in sickle cell disease

Authors: John-John B. Schnog, Esther H. Jager, Fey P. L. van der Dijs, Ashley J. Duits, Han Moshage, Fred D. Muskiet, Frits A. J. Muskiet

Published in: Annals of Hematology | Issue 6/2004

Login to get access

Abstract

Over the last few years, a pivotal role has been ascribed to reduced nitric oxide (NO) availability as a contributing factor to the vaso-occlusive process of sickle cell disease. We investigated whether arginine metabolism in sickle cell patients is different from healthy controls. Blood samples were drawn by venipuncture in the fasting state from 8 clinically asymptomatic HbSS patients and 14 race-matched HbAA controls. HbSS patients had decreased plasma arginine (p=0.001) and increased proline (p=0.015) levels as compared to controls. Ratios of arginine to ornithine (p<0.001), proline (p<0.001), glutamate (p=0.003), and citrulline (p=0.026) were lower in HbSS patients. There were significant correlations of ornithine (rs=−0.71, p=0.047), citrulline (rs=−0.79, p=0.021), arginine/ornithine (rs=0.93, p=0.001), and arginine/citrulline (rs=0.81, p=0.015) to hemoglobin and of arginine/proline (rs=−0.76, p=0.028) and citrulline (rs=0.71, p=0.048) to leukocyte counts. These data indicate that in clinically asymptomatic sickle cell patients increased arginine metabolism is shifted to the arginase pathway and that this seems to be more profound in patients with higher hemolytic rates and leukocyte counts.
Literature
1.
2.
go back to reference Frenette PS (2002) Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol 9:101–106CrossRefPubMed Frenette PS (2002) Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol 9:101–106CrossRefPubMed
3.
go back to reference Francis RB Jr (1991) Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagul Fibrinolysis 2:341–353PubMed Francis RB Jr (1991) Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagul Fibrinolysis 2:341–353PubMed
4.
go back to reference Reiter CD, Gladwin MT (2003) An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol 10:99–107CrossRefPubMed Reiter CD, Gladwin MT (2003) An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol 10:99–107CrossRefPubMed
5.
go back to reference Schechter AN, Gladwin MT (2003) Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med 348:1483–1485CrossRefPubMed Schechter AN, Gladwin MT (2003) Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med 348:1483–1485CrossRefPubMed
6.
go back to reference Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM (1996) Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci U S A 93:9114–9119CrossRefPubMed Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM (1996) Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci U S A 93:9114–9119CrossRefPubMed
7.
go back to reference Space SL, Lane PA, Pickett CK, Weil JV (2000) Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium. Am J Hematol 63:200–204CrossRefPubMed Space SL, Lane PA, Pickett CK, Weil JV (2000) Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium. Am J Hematol 63:200–204CrossRefPubMed
8.
go back to reference Belhassen L, Pelle G, Sediame S, Bachir D, Carville C, Bucherer C, Lacombe C, Galacteros F, Adnot S (2001) Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 97:1584–1589CrossRefPubMed Belhassen L, Pelle G, Sediame S, Bachir D, Carville C, Bucherer C, Lacombe C, Galacteros F, Adnot S (2001) Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 97:1584–1589CrossRefPubMed
9.
go back to reference Gladwin MT, Schechter AN, Ognibene FP, Coles WA, Reiter CD, Schenke WH, Csako G, Waclawiw MA, Panza JA, Cannon RO 3rd (2003) Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 107:271–278CrossRefPubMed Gladwin MT, Schechter AN, Ognibene FP, Coles WA, Reiter CD, Schenke WH, Csako G, Waclawiw MA, Panza JA, Cannon RO 3rd (2003) Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 107:271–278CrossRefPubMed
10.
go back to reference Mori M, Gotoh T (2000) Regulation of nitric oxide production by arginine metabolic enzymes. Biochem Biophys Res Commun 275:715–719CrossRefPubMed Mori M, Gotoh T (2000) Regulation of nitric oxide production by arginine metabolic enzymes. Biochem Biophys Res Commun 275:715–719CrossRefPubMed
11.
go back to reference Hallemeesch MM, Lamers WH, Deutz NE (2002) Reduced arginine availability and nitric oxide production. Clin Nutr 21:273–279CrossRefPubMed Hallemeesch MM, Lamers WH, Deutz NE (2002) Reduced arginine availability and nitric oxide production. Clin Nutr 21:273–279CrossRefPubMed
12.
go back to reference Morris SM Jr (2002) Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr 22:87–105CrossRefPubMed Morris SM Jr (2002) Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr 22:87–105CrossRefPubMed
13.
go back to reference Van der Dijs FP, van den Berg GA, Schermer JG, Muskiet FD, Landman H, Muskiet FA (1992) Screening cord blood for hemoglobinopathies and thalassemia by HPLC. Clin Chem 38:1864–1869PubMed Van der Dijs FP, van den Berg GA, Schermer JG, Muskiet FD, Landman H, Muskiet FA (1992) Screening cord blood for hemoglobinopathies and thalassemia by HPLC. Clin Chem 38:1864–1869PubMed
14.
go back to reference Van der Dijs, Schnog JJ, Brouwer DA, Velvis HJ, van den Berg GA, Bakker AJ, Duits AJ, Muskiet FD, Muskiet FA (1998) Elevated homocysteine levels indicate suboptimal folate status in pediatric sickle cell patients. Am J Hematol 59:192–198CrossRefPubMed Van der Dijs, Schnog JJ, Brouwer DA, Velvis HJ, van den Berg GA, Bakker AJ, Duits AJ, Muskiet FD, Muskiet FA (1998) Elevated homocysteine levels indicate suboptimal folate status in pediatric sickle cell patients. Am J Hematol 59:192–198CrossRefPubMed
15.
go back to reference Vichinsky E, Kleman K, Embury S, Lubin B (1981) The diagnosis of iron deficiency anemia in sickle cell disease. Blood 58:963–968PubMed Vichinsky E, Kleman K, Embury S, Lubin B (1981) The diagnosis of iron deficiency anemia in sickle cell disease. Blood 58:963–968PubMed
16.
go back to reference Moshage H, Kok B, Huizenga JR, Jansen PL (1995) Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 41:892–896PubMed Moshage H, Kok B, Huizenga JR, Jansen PL (1995) Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 41:892–896PubMed
17.
go back to reference Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO 3rd, Schechter AN, Gladwin MT (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8:1383–1389CrossRefPubMed Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO 3rd, Schechter AN, Gladwin MT (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8:1383–1389CrossRefPubMed
18.
go back to reference Enwonwu CO, Xu XX, Turner E (1990) Nitrogen metabolism in sickle cell anemia: free amino acids in plasma and urine. Am J Med Sci 300:366–371PubMed Enwonwu CO, Xu XX, Turner E (1990) Nitrogen metabolism in sickle cell anemia: free amino acids in plasma and urine. Am J Med Sci 300:366–371PubMed
19.
go back to reference Lopez BL, Kreshak AA, Morris CR, Davis-Moon L, Ballas SK, Ma XL (2003) L-arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department. Br J Haematol 120:532–534CrossRefPubMed Lopez BL, Kreshak AA, Morris CR, Davis-Moon L, Ballas SK, Ma XL (2003) L-arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department. Br J Haematol 120:532–534CrossRefPubMed
20.
go back to reference Van der Jagt DJ, Kanellis GJ, Isichei C, Patuszyn A, Glew RH (1997) Serum and urinary amino acid levels in sickle cell disease. J Trop Pediatr 43:220–225PubMed Van der Jagt DJ, Kanellis GJ, Isichei C, Patuszyn A, Glew RH (1997) Serum and urinary amino acid levels in sickle cell disease. J Trop Pediatr 43:220–225PubMed
21.
go back to reference Morris CR, Kuypers FA, Larkin S, Vichinsky EP, Styles LA (2000) Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 22:515–520CrossRefPubMed Morris CR, Kuypers FA, Larkin S, Vichinsky EP, Styles LA (2000) Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 22:515–520CrossRefPubMed
22.
go back to reference Morris CR, Morris SM Jr, Hagar W, Van Warmerdam J, Claster S, Kepka-Lenhart D, Machado L, Kuypers FA, Vichinsky EP (2003) Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 168:63–69CrossRefPubMed Morris CR, Morris SM Jr, Hagar W, Van Warmerdam J, Claster S, Kepka-Lenhart D, Machado L, Kuypers FA, Vichinsky EP (2003) Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 168:63–69CrossRefPubMed
23.
go back to reference Schnog JB, Lard LR, Rojer RA, van der Dijs FP, Muskiet FA, Duits AJ (1998) New concepts in assessing sickle cell disease severity. Am J Hematol 58:61–66CrossRefPubMed Schnog JB, Lard LR, Rojer RA, van der Dijs FP, Muskiet FA, Duits AJ (1998) New concepts in assessing sickle cell disease severity. Am J Hematol 58:61–66CrossRefPubMed
24.
go back to reference Li H, Meininger CJ, Hawker JR Jr, Haynes TE, Kepka-Lenhart D, Mistry SK, Morris SM Jr, Wu G (2001) Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 280:E75-E82PubMed Li H, Meininger CJ, Hawker JR Jr, Haynes TE, Kepka-Lenhart D, Mistry SK, Morris SM Jr, Wu G (2001) Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 280:E75-E82PubMed
25.
go back to reference Wagener, Feldman E, de Witte T, Abraham NG (1997) Heme induces the expression of adhesion molecules ICAM-1, VCAM-1, and E selectin in vascular endothelial cells. Proc Soc Exp Biol Med 216:456–463PubMed Wagener, Feldman E, de Witte T, Abraham NG (1997) Heme induces the expression of adhesion molecules ICAM-1, VCAM-1, and E selectin in vascular endothelial cells. Proc Soc Exp Biol Med 216:456–463PubMed
26.
go back to reference Schnog JB, Rojer RA, Mac Gillavry MR, ten Cate H, Brandjes DP, Duits AJ (2003) Steady-state sVCAM-1 serum levels in adults with sickle cell disease. Ann Hematol 82:109–113PubMed Schnog JB, Rojer RA, Mac Gillavry MR, ten Cate H, Brandjes DP, Duits AJ (2003) Steady-state sVCAM-1 serum levels in adults with sickle cell disease. Ann Hematol 82:109–113PubMed
27.
go back to reference Serjeant G, Serjeant B, Stephens A, Roper D, Higgs D, Beckford M, Cook J, Thomas P (1996) Determinants of haemoglobin level in steady-state homozygous sickle cell disease. Br J Haematol 92:143–149CrossRefPubMed Serjeant G, Serjeant B, Stephens A, Roper D, Higgs D, Beckford M, Cook J, Thomas P (1996) Determinants of haemoglobin level in steady-state homozygous sickle cell disease. Br J Haematol 92:143–149CrossRefPubMed
28.
go back to reference Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330:1639–1644PubMed Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330:1639–1644PubMed
29.
go back to reference Lard LR, Mul FP, de Haas M, Roos D, Duits AJ (1999) Neutrophil activation in sickle cell disease. J Leukoc Biol 66:411–415PubMed Lard LR, Mul FP, de Haas M, Roos D, Duits AJ (1999) Neutrophil activation in sickle cell disease. J Leukoc Biol 66:411–415PubMed
30.
go back to reference Cynober LA (2002) Plasma amino acid levels with a note on membrane transport: characteristics, regulation, and metabolic significance. Nutrition 18:761–766CrossRefPubMed Cynober LA (2002) Plasma amino acid levels with a note on membrane transport: characteristics, regulation, and metabolic significance. Nutrition 18:761–766CrossRefPubMed
Metadata
Title
Evidence for a metabolic shift of arginine metabolism in sickle cell disease
Authors
John-John B. Schnog
Esther H. Jager
Fey P. L. van der Dijs
Ashley J. Duits
Han Moshage
Fred D. Muskiet
Frits A. J. Muskiet
Publication date
01-06-2004
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 6/2004
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-004-0856-9

Other articles of this Issue 6/2004

Annals of Hematology 6/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine